{"id":31359,"date":"2025-11-13T14:22:12","date_gmt":"2025-11-13T07:22:12","guid":{"rendered":"https:\/\/nhathuocngocanh.com\/bp\/?p=31359"},"modified":"2025-11-13T14:22:12","modified_gmt":"2025-11-13T07:22:12","slug":"topiramate","status":"publish","type":"post","link":"https:\/\/nhathuocngocanh.com\/bp\/topiramate\/","title":{"rendered":"Topiramate"},"content":{"rendered":"

(Ph. Eur. 11.6 update)<\/p>\n

(Ph. Eur. monograph 2616)<\/p>\n

\"C12H21NO8S\"<\/p>\n

C12<\/sub>H21<\/sub>NO8<\/sub>S\u00a0 \u00a0 339.4\u00a0 \u00a0 97240-79-4<\/p>\n

Action and use<\/strong><\/p>\n

Antiepileptic.<\/p>\n

DEFINITION<\/h2>\n

2,3:4,5-Bis-O-(propan-2,2-diyl)-\u03b2-D-fructopyranose 1-sulfamate.<\/p>\n

Content<\/strong><\/p>\n

98.0 per cent to 102.0 per cent (anhydrous substance).<\/p>\n

CHARACTERS<\/h2>\n

Appearance<\/strong><\/p>\n

White or almost white, crystalline powder.<\/p>\n

Solubility<\/strong><\/p>\n

Slightly soluble in water, freely soluble in methanol and in methylene chloride.<\/p>\n

IDENTIFICATION<\/h2>\n

Infrared absorption spectrophotometry (2.2.24). Comparison with topiramate CRS.<\/p>\n

TESTS<\/h2>\n

Specific optical rotation (2.2.7)<\/p>\n

-32 to -29 (anhydrous substance). Dissolve 0.200 g in methanol R and dilute to 50.0 mL with the same solvent.<\/p>\n

Impurity A<\/strong><\/p>\n

Thin-layer chromatography (2.2.27).<\/p>\n

Test solution: Dissolve 40.0 mg of the substance to be examined in 1.0 mL of methanol R.<\/p>\n

Reference solution (a): Dissolve 10.0 mg of topiramate impurity A CRS in methanol R and dilute to 50.0 mL with the same solvent. Dilute 2.0 mL of the solution to 5.0 mL with methanol R.<\/p>\n

Reference solution (b): Dissolve 40 mg of the substance to be examined in 1 mL of reference solution (a).<\/p>\n

Plate: TLC silanised silica gel plate R.<\/p>\n

Pretreatment: Wash the plate with methanol R and allow to dry in air.<\/p>\n

Mobile phase: methanol R, acetonitrile R, 29 g\/L solution of sodium chloride R (15:35:50 V\/V\/V).<\/p>\n

Application: 5 \u03bcL.<\/p>\n

Development: Over 2\/3 of the plate.<\/p>\n

Drying: In air.<\/p>\n

Detection: Spray with a solution prepared by dissolving 3 g of phenol R in 95 mL of ethanol (96 per cent) R and carefully adding 5 mL of sulfuric acid R; allow to dry in air, then heat at 125 \u00b0C for 10 min using transmittance mode.<\/p>\n

Retardation factors: Topiramate = about 0.43; impurity A = about 0.55.<\/p>\n

System suitability: The chromatogram obtained with reference solution (b) shows 2 clearly separated spots due to topiramate and impurity A.<\/p>\n

Limit: Any spot due to impurity A is not more intense than the corresponding spot in the chromatogram obtained with reference solution (a) (0.2 per cent).<\/p>\n

Related substances<\/strong><\/p>\n

Liquid chromatography (2.2.29).<\/p>\n

Solvent mixture: acetonitrile R1, mobile phase A (20:80 V\/V).<\/p>\n

Test solution (a): Dissolve 50.0 mg of the substance to be examined in the solvent mixture and dilute to 10.0 mL with the solvent mixture.<\/p>\n

Test solution (b): Dilute 1.0 mL of test solution (a) to 20.0 mL with the solvent mixture. Dilute 5.0 mL of this solution to 50.0 mL with the solvent mixture.<\/p>\n

Reference solution (a): Dilute 1.0 mL of test solution (a) to 100.0 mL with the solvent mixture. Dilute 1.0 mL of this solution to 10.0 mL with the solvent mixture.<\/p>\n

Reference solution (b): Dissolve 15.0 mg of topiramate impurity E CRS in the solvent mixture and dilute to 50.0 mL with the solvent mixture. Dilute 5.0 mL of the solution to 200.0 mL with the solvent mixture.<\/p>\n

Reference solution (c): Dissolve 5 mg of the substance to be examined in 1 mL of a mixture of 2 volumes of acetonitrile R1, 4 volumes of water for chromatography R and 4 volumes of anhydrous formic acid R. Incubate at 60 \u00b0C for 30 min (in situ preparation of impurity C). Dilute 20 \u03bcL of the solution to 1 mL with a 25 mg\/L solution of fructose R (impurity E).<\/p>\n

Reference solution (d): Dissolve 25.0 mg of topiramate CRS in 10.0 mL of the solvent mixture and dilute to 100.0 mL with the solvent mixture. Dilute 5.0 mL of the solution to 50.0 mL with the solvent mixture.<\/p>\n

Column:
\n\u2014 size: l = 0.10 m, \u00d8 = 4.6 mm;
\n\u2014 stationary phase: end-capped solid core pentafluorophenylpropylsilyl silica gel for chromatography R (2.6 \u03bcm);
\n\u2014 temperature: 40 \u00b0C.<\/p>\n

Mobile phase:
\n\u2014 mobile phase A: 1.93 g\/L solution of ammonium acetate R adjusted to pH 3.5 with glacial acetic acid R;
\n\u2014 mobile phase B: acetonitrile R1;<\/p>\n\n\n\n\n\n\n
Time<\/strong><\/td>\nMobile phase A<\/strong><\/td>\nMobile phase B<\/strong><\/td>\n<\/tr>\n
0 – 5<\/td>\n80<\/td>\n20<\/td>\n<\/tr>\n
5 – 15<\/td>\n80 \u2192 50<\/td>\n20 \u2192 50<\/td>\n<\/tr>\n
15 – 15.1<\/td>\n50 \u2192 80<\/td>\n50 \u2192 20<\/td>\n<\/tr>\n<\/tbody>\n<\/table>\n

Flow rate: 1.0 mL\/min.<\/p>\n

Detection: Charged aerosol detector \u2014 range: 100 pA; filter: none.<\/p>\n

Injection: 20 \u03bcL of test solution (a) and reference solutions (a), (b) and (c).<\/p>\n

Identification of impurities: Use the chromatogram obtained with reference solution (b) to identify the peak due to impurity E.<\/p>\n

Relative retention: With reference to topiramate (retention time = about 5.6 min), impurity E = about 0.18; impurity C = about 0.25.<\/p>\n

System suitability: Reference solution (c) \u2014 resolution: minimum 4.5 between the peaks due to impurities E and C.<\/p>\n

Calculation of percentage contents:
\n\u2014 For impurity E, use the concentration of impurity E in reference solution (b) and the height of the peak due to impurity E;
\n\u2014 For impurities other than E, use the concentration of topiramate in reference solution (a).<\/p>\n

Limits:
\n\u2014 Impurity E: maximum 0.15 per cent;
\n\u2014 Unspecified impurities: for each impurity, maximum 0.10 per cent;
\n\u2014 Total: maximum 0.2 per cent;
\n\u2014 Reporting threshold: 0.05 per cent.<\/p>\n

Water (2.5.12)<\/p>\n

Maximum 0.5 per cent, determined on 1.000 g.<\/p>\n

Sulfated ash (2.4.14)<\/p>\n

Maximum 0.1 per cent, determined on 1.0 g.<\/p>\n

ASSAY<\/h2>\n

Liquid chromatography (2.2.29) as described in the test for related substances with the following modifications.<\/p>\n

Injection: Test solution (b) and reference solution (d).<\/p>\n

Calculate the percentage content of C12<\/sub>H21<\/sub>NO8<\/sub>S taking into account the assigned content of topiramate CRS.<\/p>\n

IMPURITIES<\/h2>\n

Specified impurities: A, E.<\/p>\n

Other detectable impurities: The following substances, if present at a sufficient level, would be detected by one or other of the tests in the monograph. They are limited by the general acceptance criterion for other\/unspecified impurities and\/or by the general monograph Substances for pharmaceutical use (2034). It is therefore not necessary to identify these impurities for demonstration of compliance. See also 5.10. Control of impurities in substances for pharmaceutical use: B, C, D.<\/p>\n

\"A.<\/p>\n

A. 2,3:4,5-bis-O-(propan-2,2-diyl)-\u03b2-D-fructopyranose<\/p>\n

\"B.<\/p>\n

B. 2,3:4,5-bis-O-(propan-2,2-diyl)-\u03b2-D-fructopyranose 1-[N-(diethylcarbamoyl)sulfamate]\n

\"C.<\/p>\n

C. 2,3-O-(propan-2,2-diyl)-\u03b2-D-fructopyranose 1-sulfamate<\/p>\n

\"D.<\/p>\n

D. 2,3:4,5-bis-O-(propan-2,2-diyl)-\u03b2-D-fructopyranose 1-[N-[[[2,3:4,5-bis-O-(propan-2,2-diyl)-\u03b2-D-fructopyranosyl]oxy]carbamoyl]sulfamate]\n

\"E.<\/p>\n

E. D-fructopyranose (fructose)<\/p>\n","protected":false},"excerpt":{"rendered":"

(Ph. Eur. 11.6 update) (Ph. Eur. monograph 2616) C12H21NO8S\u00a0 \u00a0 339.4\u00a0 \u00a0 97240-79-4 Action and use Antiepileptic. DEFINITION 2,3:4,5-Bis-O-(propan-2,2-diyl)-\u03b2-D-fructopyranose 1-sulfamate. Content 98.0 per cent to 102.0 per cent (anhydrous substance). CHARACTERS Appearance White or almost white, crystalline powder. Solubility Slightly soluble in water, freely soluble in methanol and in methylene chloride. IDENTIFICATION Infrared absorption spectrophotometry…<\/p>\n","protected":false},"author":4,"featured_media":31362,"comment_status":"open","ping_status":"open","sticky":false,"template":"","format":"standard","meta":{"_acf_changed":false,"footnotes":""},"categories":[174],"tags":[],"class_list":["post-31359","post","type-post","status-publish","format-standard","has-post-thumbnail","hentry","category-medicinal-substances"],"acf":[],"_links":{"self":[{"href":"https:\/\/nhathuocngocanh.com\/bp\/wp-json\/wp\/v2\/posts\/31359","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/nhathuocngocanh.com\/bp\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/nhathuocngocanh.com\/bp\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/nhathuocngocanh.com\/bp\/wp-json\/wp\/v2\/users\/4"}],"replies":[{"embeddable":true,"href":"https:\/\/nhathuocngocanh.com\/bp\/wp-json\/wp\/v2\/comments?post=31359"}],"version-history":[{"count":2,"href":"https:\/\/nhathuocngocanh.com\/bp\/wp-json\/wp\/v2\/posts\/31359\/revisions"}],"predecessor-version":[{"id":31369,"href":"https:\/\/nhathuocngocanh.com\/bp\/wp-json\/wp\/v2\/posts\/31359\/revisions\/31369"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/nhathuocngocanh.com\/bp\/wp-json\/wp\/v2\/media\/31362"}],"wp:attachment":[{"href":"https:\/\/nhathuocngocanh.com\/bp\/wp-json\/wp\/v2\/media?parent=31359"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/nhathuocngocanh.com\/bp\/wp-json\/wp\/v2\/categories?post=31359"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/nhathuocngocanh.com\/bp\/wp-json\/wp\/v2\/tags?post=31359"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}